CABS Clinical Development Workshop
Date: April 26, 2025
Time: 9:00 AM – 1:30 PM
Location: 1633 Old Bayshore HWY #280, Burlingame, CA 94010
Join Us for the CABS Clinical Development Workshop!
Unlock the path to market approval! Gain valuable insights into clinical development from industry experts at Genentech and ChemoCentryx/Amgen. This half-day workshop will cover key aspects of clinical trials, including study design, statistical considerations, clinical pharmacology, and essential elements of clinical trial protocols. Don’t miss this opportunity to enhance your knowledge and expand your professional network! Register now!
Workshop Agenda
Speakers’ bios and phots:
1. Shichang Miao, PhD
Ex-VP PreclinDev & ClinPharm, ChemoCentryx/Amgen
Dr Shichang Miao, PhD, is a seasoned DMPK/ClinPharm scientist and drug developer and biotech investor. During his career, he worked at several biotech companies in the San Francisco Bay Area, including Tularik, ChemoCentryx and Amgen. At ChemoCentryx, as Vice President of Preclinical Development & Clinical Pharmacology, he led a team to conduct the preclinical assessment and clinical pharmacology studies for the development of Tavneos® (avacopan), which was approved in 2021 by the FDA for the treatment of ANCA-associated vasculitis, leading to the acquisition of ChemoCentryx by Amgen in 2022. He received his PhD in organic chemistry and post-doctoral training in biochemistry at the University of British Columbia (Vancouver, Canada).
Dr. Miao made significant contributions to the life science community; he is the founder and president of Pharmaceutical & Bioscience Society International (PBSS) and is a former president of the Chinese American BioPharmaceutical Society (CABS). He has also been serving as an advisor to Stanford University’s SPARK translational medicine program since 2015 and as a member of the screening committee of Life Science Angels, a leading life science angel investment group based in Silicon Valley, since 2018.
2. Sara Glickstein Bar-Zeev, PhD
Principal Clinical Scientist, Genentech
Sara Glickstein Bar-Zeev, Ph.D., is a Principal Clinical Scientist in gRED OMNI Early Clinical Development, Genentech, Inc in South San Francisco.
Her area of focus includes first-in-human and proof-of-concept clinical trials in non-oncology indications. She received her PhD at Cornell University in Neurobiology. Before joining Genentech in 2017, she spent a decade in Medical Communications, focusing on publication strategy and medical writing, and previously held research faculty positions at Cornell and Columbia Universities. She has completed fellowships in ophthalmology and psychiatry and has published more than 30 research papers during her time as an academic scientist.
3. Chen Chen, PhD
Principal Statistical Scientist, Genentech
Chen Chen is a Principal Statistical Scientist in PDD Early Development Biometrics at Genentech, where he has worked since 2018. He has made significant contributions to molecule projects, research projects, and due diligence projects across multiple therapeutic areas, including ophthalmology, neuroscience, and immunology. Chen has effectively led data science teams through various stages of clinical development. In addition, he established collaborations with academic researchers in statistics and clinical development to explore and develop novel statistical methods and clinical techniques. Chen received his PhD in statistics from George Washington University and worked as a postdoctoral fellow at Penn State University before joining Genentech.
Please scan the QR code below to finish the registration!
For questions, please email: liping.meng@cabsweb.org
Sponsor: Sanyou Biopharmaceuticals Co., Ltd.
